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E-mail address: kanopka@ibt.lt (A. Kanopka).Monoamine oxidase B (MAO-B) plays an important role in the metabolism of neuroactive and vaso-
active amines in the central nervous system and peripheral tissues. Increased levels of MAO-B mRNA
and enzymatic activity have been reported in platelets from patients with Parkinson’s and Alzhei-
mer’s diseases, however the triggers of enhanced mRNA levels are unknown. Our results demon-
strate for the ﬁrst time that G/A dimorphism in intron 13 sequence creates splicing enhancer thus
stimulating intron 13 removal efﬁciency. The increased MAO-B protein levels might serve as a sur-
rogate marker for – Parkinson disease.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction and brain. However, some cell types predominantly express oneParkinson’s disease, the second most common neurodegenera-
tive disease, is associated with selective degeneration of nigrostri-
atal dopamine neurons, which results in a symptom complex
consisting of tremor, rigidity and slowed movements. About 10%
of Parkinson’s disease cases are caused by a mutation in one of sev-
eral different genes, most are thought to result from a combination
of variable environmental exposures superimposed on an individ-
ual’s composite genetic susceptibility [1]. It is well established that
MAO-B inhibitors delay progression of Alzheimer’s and Parkinson’s
diseases [2,3].
Monoamine oxidase (MAO) exists in two functional forms:
MAO-A and MAO-B. The genes of both protein isoforms possess
identical exon–intron organization, but have different substrate
and inhibitor speciﬁcities and are encoded by separate genes
located tail-to-tail on the X chromosome. While MAO-A preferen-
tially degrades serotonine, norepinephrine and is selectively inhib-
ited by clorgyline, the MAO-B is more efﬁcient in metabolizing
phenylethylamine and benzylamine and is selectively inhibited
by deprenyl [4]. Both enzymes are present in various tissues
throughout the body with the highest levels of expression in liverchemical Societies. Published by E
munology and Cell Biology,
o 8, 02241 Vilnius, Lithuania.type of MAO: placenta cells express mainly MAO-A, while platelets
and lymphocytes cells posses only MAO-B activity [4,5]. The ability
of monoamine oxidases to metabolize neurotransmitters suggests
their role in the etiology of human behavioral traits and neuropsy-
chiatric disorders.
Several DNA polymorphisms in the MAO-B gene have been de-
scribed. Seven out of ten single-nucleotide polymorphisms (SNP) in
the MAO-B gene have been identiﬁed in African-American or/and
Native-American populations but were not detected in Caucasians
and Asians. The only SNP found in all human populations, that is
the G/A dimorphism in intron 13 sequence, located 36 b.p. up-
stream from the intron 13–exon 14 boundary. The ‘‘A’’ allele was
previously associated with an approximately two fold risk of Par-
kinson disease [6–8].
In the present studywe have examined the impact of A/G dimor-
phism in MAO-B gene intron 13 sequence for pre-mRNA splicing.
Our studies revealed that A/Gdimorphism in a non-coding sequence
of MAO-B gene in platelets regulates MAO-B mRNA formation and
MAO-B protein expression levels and could serve as diseasemarker.
2. Materials and methods
2.1. Pre-mRNA substrates
DNA constructs were made from the MAO-B gene (spanning
exon 13-intron 13-exon 14) by PCR using appropriate primer pairs:lsevier B.V. All rights reserved.
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CTTTGCAGGCACC)-30; P2: 50-d(TTCCTAAGCT TCTGGAGAGTTGGTCT
CCAGG)-30) and P3–P4 – constructs 30 fragment (P3: 50-d(TTCC
TCTCGAGCAGACTCTGGTTCTGACTGC)-30 P4: 50-d(AAGGAAAGCTTT
TATACCA CAGGAGAAAGACC)-30. PCR fragments (MaoBa and
MaoBg) through SacI/HindIII and HindIII/XhoI restriction endonucle-
ase sites respectively were cloned into pBluescript II KS (+) plasmid
DNA (Thermo Fisher scientiﬁc).
2.2. T7 transcription and pre-mRNA splicing in vitro
Labeled pre-mRNAs from the plasmids were generated in an
in vitro transcription reaction using T7 RNA polymerase and
[32P]CTP. Transcription reaction products were puriﬁed. crossBrie-
ﬂy, splicing reactions (25 ll) contained: 10 fmol in vitro tran-
scribed, capped and [32P]-labeled pre-mRNA, 20% nuclear extract
(CilBiotech), 2.6% (w/v) polyvinyl alcohol, 2.8 mM MgCl2, 2 mM
ATP, 20 mM phosphocreatine and buffer D (20% (w/v) glycerol,
20 mM HEPE pH 7.9, 100 mM KCl, 0.2 mM EDTA, 0.5 mM DTT,
0.3 mM PMSF). Reactions were incubated 0.5–2 h at 30 C followed
by proteinase K digestion (40 lg) (Thermo Fisher scientiﬁc) for
30 min at 37 C, extracted with phenol–chloroform and ethanol
precipitated. Pre-mRNA splicing reaction products were resolved
on 8% denaturing polyacrylamide gels.
2.3. Splicesome assembly
Splicesome assembly performed under splicing conditions as
described above. Reactions were incubated at 30 C either for 0
or 20 min. Complexes were separated on 1,2 % low melting agarose
gels [9].
2.4. UV crosslinking and ‘‘ﬁshing out’’ bound proteins
UV crosslinking was performed as earlier described [10]. HeLa-
NE (100 lg proteins) were incubated with 25–40 fmol [32P] and
biotin double labeled RNA in splicing buffer lacking creatinine
phosphate (25 ll total volume), exposed to 254 nm for 15 min on
ice. Bound to pre-mRNA proteins separated from unbound proteins
using streptavidin beads (Invitrogen), digested with 10 lg RNase A
(Thermo Fisher scientiﬁc) at 30 C for 30 min., separated on a 10%
SDS–polyacrylamide gel and transferred to the membrane. Mem-
brane incubated with anti-SR antibodies (Santa Cruz) washed,
and incubated with secondary antibody (Dako). Membrane devel-
oped using ECL reagent (GE Healthcare).
2.5. Preparation and analysis of the blood samples
Blood samples from healthy control individuals and patients
withParkinson’s diseasewere fractionatedusingFicoll gradient cen-
trifugation. The upper (platelet) fractionwas collected. The proteins
(20 lg/per lane) were separated on a 10% SDS–polyacrylamide gel,
transferred to the nitrocellulose membrane and detected using
anti-Mao-B antibody (Santa Cruz). DNA from platelet fraction was
isolated as described [9]. For MAO-B intron 13 sequence ampliﬁca-
tion P3–P4 primer pair was used.
3. Results
3.1. MAO-B protein levels are enhanced in platelet fraction of
Parkinsonian patients
Earlier it has been demonstrated that enzymatic activity of
MAO-B is increased in platelet fraction of parkinsonian patients
[11,12], but the occasion, until this time, of this increase is not
understood. We have compared MAO-B protein expression levelsin the platelet fraction, obtained from blood of healthy persons
and from patients with Parkinson disease. Data presented in
Fig. 1A,B show elevated levels of MAO-B protein expression in PD
patient platelets fraction when compared to healthy individuals.
The elevated MAO-B protein expression levels were detected in
all eight tested PD patient blood samples. This indicates that not
only the enzymatic activity and mRNA levels of MAO-B is increased
in the platelet fraction of Parkinsonian patients but that MAO-B
protein levels are also signiﬁcantly upregulated. The isolated plate-
let DNA sequencing data from the same patients showed the
association of A-allele with the enhanced MAO-B expression levels
(supplemental Fig. 1).
3.2. SNP in MAO-B gene intron 13 sequence inﬂuences intron removal
efﬁciency
Dimorphism of MAO-B gene in intron 13 sequence does not
cause changes in the coding sequence, since it is located within
an intron, and does not affect the consensus acceptor and donor
sites [13]. In order to investigate the inﬂuence of G/A dimorphism
in MAO-B gene intron 13 for pre-mRNA splicing, we have created
constructs containing either ‘‘G’’ allele (MaoBg) or ‘‘A’’ allele
(MaoBa) intronic sequences (Fig. 1C). From these constructs, the
transcription reactions in vitro were performed and the transcribed
pre-mRNAs were tested in the in vitro splicing assays using nuclear
extracts prepared from HeLa cells (HeLa-NE). Splicing assays re-
vealed the enhanced efﬁciency of MaoBa pre-mRNA splicing when
compared to MaoBg construct splicing. The intron 13 containing
the ‘‘A’’ allele is removed more efﬁciently than ‘‘G’’ allele (Fig. 1D
and E).
To elucidate whether one nucleotide change in the intronic se-
quence, close to 30 splice site is sufﬁcient to inﬂuence pre-mRNA
splicing efﬁciency, we have constructed chimeric b globin con-
structs where intronic 30 splice site sequence (69 nt.) of b-globin
pre-mRNA substituted with MAO-B intron 13 sequences, contain-
ing G or A alleles (b-gl/MaoBg and b-gl/MaoBa constructs, respec-
tively) (Fig. 2A). These chimeric constructs were tested in the
in vitro splicing assays. Splicing results illustrate that b-gl/MaoBa
construct was also spliced more efﬁciently than b-gl/MaoBg con-
struct (Fig. 2B and C). Collectively, the obtained results indicate
that a single nucleotide dimorphism in a non-coding sequence
may greatly inﬂuence intron removal efﬁciency.
3.3. G/A dimorphism in intron 13 sequence does not affect branch
point site
It has been previously shown that changes from G nucleotide to
A in the intronic sequence close to 30 splice site can inﬂuence
branch point location during splicesome formation [14]. To estab-
lish whether this dimorphism affects branching point location dur-
ing splicesome formation, we used bioinformatics analysis as
described in [15]. The results of this analysis revealed that the G/
A dimorphism in intron 13 sequence does not affect branch point
site as shown in the supplemental material Fig. S2.
3.4. ‘‘A’’ allele in intron 13 sequence increases the efﬁciency of early-
stage splicesomal complex assembly
To study at which stage of the splicesome formation the
efﬁciency of intron removal is affected, we used a splicesome
assembly assay by performing SDS–PAGE electrophoresis under
non-denaturing conditions. Our results demonstrate that splice-
some complex formation on MaoBa pre-mRNA transcript was more
efﬁcient as compared to the complex formation on the MaoBg tran-
script (Fig. 3A). Since under the tested conditions only the early-
stage splicesome complexes can be detected, this ﬁnding indicates
Fig. 1. MAO-B expression levels and the effect of ‘‘A’’ allele for Mao-B intron 13 splicing. (A) Mao-B expression levels in the platelet fraction from one healthy individuals and
one patient with Parkinson disease. YY1 – loading control. (B) Quantitation of Mao-B protein expression levels in the platelet fraction from PD patients normalized against
expression levels of healthy individuals (n = 8). (C) Schematic ﬁgure showing the pre-mRNA constructs used in the in vitro splicing assays, MaoBg – contains the G allele,
MaoBa – the A allele. Enlargement shows the nucleotide sequence, the SNP dimorphism is indicated by arrow. The branch point is indicated by an asterisk. (D) Time course of
the in vitro splicing reaction of MaoBg and MaoBa transcripts. (E) Calculation of spliced product formation (data from three independent experiments) using scanning imager
program (Fuji FLA-5100). Quantiﬁed spliced product is shown by arrow in Fig. 1D.
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the efﬁciency of early-stage splicesomal complex assembly.
3.5. SR proteins interact more efﬁciently with intronic sequence
containing ‘‘A’’ allele
Further, we have analyzed how proteins from the nuclear ex-
tracts of HeLa (HeLa-NE) cells interact with MaoBg and MaoBa
pre-mRNA transcripts. We incubated the transcripts with the
HeLa-NE, followed by the UV crosslinking assay, and analyzed by
SDS–PAGE electrophoresis. The results presented in Fig. 3B show
that HeLa-NE proteins interacted with MaoBa pre-mRNA more efﬁ-
ciently when compared to MaoBg. To further identify the splicing
factors interacting with pre-mRNAs, we have cross-linked proteinsfrom HeLa-NE to MaoBg and MaoBa pre-mRNAs using ultraviolet
radiation. The pre-mRNAs were double labeled with [32P] and bio-
tin. Proteins crosslinked to pre-mRNA, were ‘‘ﬁshed out’’ from the
HeLa-NE using streptavidin-coupled beads and analyzed by Wes-
tern-blot analysis. As shown in Fig. 3c, SR proteins interacted more
efﬁciently with the sequence containing an A nucleotide when
compared to a G nucleotide (Fig. 3C). Thus, the G/A dimorphism
in the intronic sequence create an SR protein binding site and as
consequence, activate more efﬁcient intron removal.
3.6. Effect of SR proteins on MAO-B gene intron 13 removal
Addition of isolated classical SR proteins [16] into splicing reac-
tions showed that MaoBg constructs required much higher SR
Fig. 2. Effect of A/G polymorphism in the intron sequence for chimeric pre-mRNAs splicing. (A) Pre-mRNA splicing chimeric constructs used in the slicing reaction. (B) Time
course (0–2 h) of b-gl/MaoBg (lanes 2–5) and b-gl/MaoBa (lanes 6–9) chimeric construct splicing reaction in vitro: lane 1 – b-globin construct splicing, lanes 2,6 reactions
incubated – 0 h, lanes 3,5 – 0.5 h, lanes 4,8 – 1 h, lanes 5,9–2 h. (C) Calculation of spliced product formation (data from three independent experiments) using scanning imager
program (Fuji FLA-5100). Quantiﬁed spliced product is shown by arrow in Fig. 2B.
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constructs, while higher amounts of SR proteins had only a slight
effect on intron A allele removal (Fig. 3D and E). These results indi-
cate that A nucleotide in the intronic sequence creates a binding
site for the SR proteins required to recruit components of the basal
splicing machinery more efﬁciently by increasing intron removal
efﬁciency.
4. Discussion
Altered levels of MAO-B have previously been associated with a
number of psychiatric and neurological conditions [11,17,18]. In-
creased levels MAO-B enzymatic activity are found in patientsbrains with Parkinson’s and Alzheimer’s disease [19]. It is shown
that MAO-B inhibitors delay progression of Alzheimer’s and Par-
kinson’s diseases [2,3]. Our data shows that platelet fraction of Par-
kinsonian patients also possesses increased MAO-B protein
expression levels (Fig. 1A) that might explain detected increase
in enzymatic activity of this enzyme in platelets, and we also
showed that allele A is associated with this increase.
Pre-mRNA splicing plays a very important role in the gene
expression. The vast majority of human genes contain introns,
most pre-mRNAs undergo splicing, and disruption of the normal
splicing patterns can cause or modify human disease. The molecu-
lar mechanisms that regulate splice site usage are beginning to
emerge and show that transcription and pre-mRNA processing
Fig. 3. Activation of intron 13 splicing occurs at an early stage. (A) Quantiﬁcation results (from three independent experiments) of splicesomal assembly on MaoBg and MaoBa
pre-mRNAs. (B) Radiogram of UV crosslinking products formed between HeLa-NE proteins and [32P] labeled MaoBg and MaoBa pre-mRNA transcripts (crosslinked products
indicated by arrow) (C) Western blot analysis of HeLa-NE proteins cross-linked to MaoBg or MaoBa pre-mRNA developed with anti-SR antibody (differentially interacting SR
proteins indicated by arrow). (D) Effect of puriﬁed SR proteins on MaoBg and MaoBa transcript splicing. (E) Calculation of spliced product formation (data from three
independent experiments) using scanning imager program (Fuji FLA-5100). Quantiﬁed spliced product is shown by arrow in Fig. 3D. a-Actin was used as loading control.
3702 E. Jakubauskiene et al. / FEBS Letters 586 (2012) 3698–3704are integrated processes that can be modiﬁed by cellular signals.
Several diseases are caused by mutations in the sequences that
regulate pre-mRNA processing. Their molecular characterizationindicates that contributions of pre-mRNA splicing defects to hu-
man diseases have been underestimated. Several neurological dis-
orders highlight the importance of the products of pre-mRNA
E. Jakubauskiene et al. / FEBS Letters 586 (2012) 3698–3704 3703splicing. Understanding of the molecular mechanisms of
pre-mRNA splicing allows the development of therapeutic strate-
gies [20,21].
G/A dimorphism in intron 13 sequence, located 36 base pairs
upstream from the intron 13–exon 14 boundary. The branch point
sequences on pre-mRNA usually are located 18–40 nt. upstream of
a splice acceptor site. In the branch point consensus sequence
YNYURAC (Y = C or T; R = G or A; N = any base) the A at position
6 is critical for formation of a mammalian splice intermediate,
the lariat structure. It has been shown that G to A mutation in neu-
roﬁbromatosis 2 (NF2) gene intronic sequence creates new branch
point sequence thus the new isoforms of mRNA are produced [14].
Using bioinformatics approach we could not ﬁnd any evidence that
G/A dimorphism in the intron sequence close to 30 splice site
affects branch point location in MAO-B gene intron 13.
Most eukaryotic genes contain introns, which are co-transcrip-
tionally removed from precursor transcripts by RNA splicing. The
mechanisms by which pre-mRNA splicing is regulated are poorly
understood. Exon recognition and splicing requires the presence
of basic ‘‘classic’’ splice sites (the branch point, polypyrimidine
tract, and the splice sites). The efﬁciency of the splicing process
can be affected by the presence of auxiliary or modulating ele-
ments in some exons and introns [22]. It has been reported that
SNPs plays an essential role in gene expression regulation in hu-
mans. For many SNPs located in genes the effects on the genes
are not known. Single nuceotide variations in RNA sequence can
modulate alternative splicing or splicing efﬁciency by affecting
the basal splicing machinery or factor regulating pre-mRNA splic-
ing interaction with RNA [23,24]. For example, in humans in zinc
ﬁnger DHHC-type (DHHC – a protein domain that acts as an en-
zyme, which adds a palmitoyl chemical group to proteins in order
to anchor them to cell membranes) containing 6 (ZDHHC6) gene,
SNP nearest the intron–exon boundary directly effects splicing efﬁ-
ciency. SNPs can also lead to differential splicing: intronic SNP in
histocompatibility (minor) serpin domain containing protein gene
(HMSD) can generate a novel minor histocompatibility antigen
[23,25]. Our ﬁndings that SNP affects MAO-B gene intron 13 splic-
ing efﬁciency (Fig. 1C) complement the knowledge regarding an
essential role of SNPs in gene expression regulation.
During mRNA splicing introns are removed from pre-mRNAs by
the spliceosome, a large complex consisting of ﬁve small nuclear
RNAs (snRNAs) and many different protein factors. We found that
MAO-B intron 13 removal activation occurs at early step of splices-
omal formation (Fig. 3A), suggesting that SNP in intronic sequence
might affect splicing factor by acting at early step of splicesomal
formation that involves interaction with RNA. Certain features of
mRNAs allow the spliceosome to distinguish exons from introns,
including conserved motifs at exon/intron boundaries (i.e., splice
sites) and motifs within the introns [26].
We detected that SR proteins interact more efﬁciently with the
construct containing ‘‘A’’ allele compared to ‘‘G’’ allele (Fig. 3C).
The SR proteins contain one or more N-terminal RNA recognition
motifs and a C-terminal domains consisting mainly of alternating
arginine and serine (R/S) residues, hence the name SR proteins.
The RS domain of SR proteins is believed to recruit splicing factors
to the splicesome through multiple protein–protein contacts with
other splicing factors [27]. We have established that single nucleo-
tide change of G to A increases SR protein binding efﬁciency
(Fig. 3C) and therefore enhances intron removal efﬁciency. Splicing
enhancers are sites to which splicing activator proteins bind,
increasing the probability that a nearby site will be used as a splice
junction. These enhancers may also occur in the intron (intronic
splicing enhancers, ISE) or exon (exonic splicing enhancers, ESE).
Most of the activator proteins that bind to ISEs and ESEs are mem-
bers of the SR protein family. Such proteins contain RNA recognition
motifs and arginine and serine-rich (RS) domains [28]. It is wellrecognized that the increased binding of SR proteins facilitates
the recruitment of the components of basal splicing machinery
[29–32].
The removal of some introns from pre-mRNA occurs more rap-
idly than the others. The slower splicing events are rate limiting
factors in mRNA formation [33]. The results presented in this paper
suggest that the intron 13 removal efﬁciency from MAO-B gene
might be rate limiting factor in the MAO-B mRNA formation, and
increased intron 13 removal in the case of ‘‘A’’ allele could cause
the increased MAO-B protein expression which might contribute
to the enhanced enzymatic activity in patients with Parkinson’s
disease.
Our study is the ﬁrst attempt to identify currently unknown
mechanisms, of the enhanced MAO-B mRNA and protein levels as
well as enzymatic activity in patients with Parkinson disease.
In summary, our data demonstrate that SNP plays important
role in intron 13 removal process from MAO-B gene. This non-cod-
ing sequence removal might be a rate limiting factor in the MAO-B
mRNA formation that leads to the enhanced protein levels and
enzymatic activity in platelet fraction from patients with Parkin-
son’s disease. Our study suggests that enhanced MAO-B protein
levels in platelets might be used as disease marker.
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